
Anna Tocheva, PhD
About Me
Anna S. Tocheva, PhD is an Assistant Professor in the Department of Genetics and Genomic Sciences and a member of the Precision Immunology Institute and the Cancer Immunology Program at the The Tisch Cancer Institute. Research in the Tocheva lab is dedicated to immune checkpoint signaling and function in human T cell biology. We are specifically interested in understanding how cellular and molecular T cell differences intersect with immune checkpoint signaling to influence T cell activation and responses to immunotherapy. By leveraging these mechanistic insights, our ultimate goal is to improve patient responses to immune checkpoint-targeting immunotherapies. To achieve that, we have developed a suite of cellular and molecular immunological assays that render a granular view of T cell activation and signaling. We have established a biobank of cancer patient-derived 3D organoid-T cell co-culture models that allow personalized view of tumor-T cell interactions, and responses to immune checkpoint perturbations.
RESEARCH TOPICS: Immunology, T cells, lymphocytes, inflammation, inhibitory receptors, immune checkpoints, PD1, PD-L1, PD-L2, signaling, immunotherapy, cancer, organoid modeling, personalized medicine, cancer immuno-biology, translational research
Language
English
Position
ASSISTANT PROFESSOR | Genetics and Genomic Sciences, ASSISTANT PROFESSOR | Immunology & Immunotherapy
Research Topics
Bioinformatics, Cancer, Cellular Immunity, Genomics, Immunological Tolerance, Immunology, Personalized Medicine, Phosphorylation, Protein Kinases, Proteomics, Receptors, Signal Transduction, T Cells, Translational Research
Multi-Disciplinary Training Areas
Genetics and Genomic Sciences [GGS], Immunology [IMM]
Publications
Selected Publications
- Protocol to co-culture SCLC cells with human CD8<sup>+</sup> T cells to measure tumor cell killing and T cell activation. Subhamoy Chakraborty, Subhasree Sridhar, Kedwin Ventura, Ramja Sritharan, Anna Tocheva, Triparna Sen. STAR Protocols
- Erratum: Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer (Cell Reports Medicine (2024) 5(12), (S2666379124006232), (10.1016/j.xcrm.2024.101852)). Subhamoy Chakraborty, Utsav Sen, Kedwin Ventura, Vrinda Jethalia, Charles Coleman, Subhasree Sridhar, Avisek Banerjee, Hilal Ozakinci, Yazhini Mahendravarman, Konrad Snioch, Elisa de Stanchina, Misty D. Shields, Lewis E. Tomalin, Deniz Demircioglu, Theresa A. Boyle, Anna Tocheva, Dan Hasson, Triparna Sen. Cell Reports Medicine
- Lurbinectedin sensitizes PD-L1 blockade therapy by activating STING-IFN signaling in small-cell lung cancer. Subhamoy Chakraborty, Utsav Sen, Kedwin Ventura, Vrinda Jethalia, Charles Coleman, Subhasree Sridhar, Avisek Banerjee, Hilal Ozakinci, Yazhini Mahendravarman, Konrad Snioch, Elisa de Stanchina, Misty D. Shields, Lewis E. Tomalin, Deniz Demircioglu, Theresa A. Boyle, Anna Tocheva, Dan Hasson, Triparna Sen. Cell Reports Medicine